TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cogstate Ltd ( (AU:CGS) ) has shared an announcement.
Cogstate Ltd announced that all resolutions were passed at its 2025 Annual General Meeting, including the re-election of directors and the renewal of the Employee Equity Plan. This outcome reflects strong shareholder support and may positively impact the company’s strategic initiatives and governance, reinforcing its position in the neuroscience technology industry.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company that specializes in optimizing brain health assessments to advance the development of new medicines and enable earlier clinical insights in healthcare. The company provides rapid, reliable, and highly sensitive computerized cognitive tests and supports partners in delivering electronic clinical outcome assessment solutions. Cogstate has been supporting biopharmaceutical companies, academic institutions, and healthcare providers with digital cognitive measures for over 20 years.
Average Trading Volume: 181,386
Technical Sentiment Signal: Buy
Current Market Cap: A$410.9M
See more data about CGS stock on TipRanks’ Stock Analysis page.